Home/Moberg Pharma/Claes G. Wahlestedt

CG

Claes G. Wahlestedt

Board Member

Therapeutic Areas

Dermatology Infectious Disease

Moberg Pharma Pipeline

Drug	Indication	Phase
MOB-015	Onychomycosis (Toenail Fungus)	Marketed

Leadership Team at Moberg Pharma

Chief Executive Officer

Founder and Board Member

View full Moberg Pharma profile